Details of Disease

General Information of Disease (ID: DIS8VTJW)

• Disease Name: Neurodegenerative disorder
• Synonyms: degenerative disease; degenerative disorder
• Disease Class: 8A20-8A23: Neurodegenerative disorder
• Definition: OBSOLETE. A disorder characterized by the progressive loss of function and/or structure of the affected tissues.|The subclasses were not a disease but a feature or a process.
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS8VTJW: Neurodegenerative disorder
• ICD Code:
  ICD-11: ICD-11: 8A20-8A23
  Expand ICD-10: F10,F11,F12,F13,F14,F15,F16,F17,F18,F19,F20,G30,G31,G32,G40,G64,G90,R52,G89
  Expand ICD-9: 295,303,304,330,331,332,333,334,335,336,337,338,345,356.0,356.8,780

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RE-024	DMTCKLX	Phase 3	NA	[1]
Etazolate	DMOCID7	Phase 2	Small molecular drug	[2]
Peptide-T	DM1O7PR	Phase 2	Small molecular drug	[3]
Choroid plexus cell therapy	DMAR0SC	Phase 1/2	NA	[4]
CXB-909	DMUGMFN	Phase 1/2	NA	[5]
11C-GSK-215083	DMQ0RXA	Phase 1	NA	[6]
ANX005	DMAESIY	Phase 1	NA	[1]
CNM-Au8	DM7LTKE	Phase 1	NA	[1]
GSK4527226	DMOVMGA	Phase 1	Antibody	[7]

This Disease is Treated as An Indication in 5 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PMID27998201-Compound-22	DMS9QA7	Patented	Small molecular drug	[8]
Pyrimidine derivative 5	DMNET19	Patented	Small molecular drug	[9]
Pyrimidine derivative 6	DMBAHYO	Patented	Small molecular drug	[9]
Pyrimidine derivative 7	DMF6DUT	Patented	Small molecular drug	[9]
Tihotungstate derivative 1	DM5UI73	Patented	Small molecular drug	[9]

This Disease is Treated as An Indication in 9 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Posatirelin	DML6EWH	Discontinued in Phase 3	Small molecular drug	[10]
TGP-580	DMYN6G0	Discontinued in Phase 2	NA	[11]
ABS-205	DMALPDW	Terminated	NA	[16]
CEP-751	DM956N7	Terminated	Small molecular drug	[17]
EUK-207	DMLA3P1	Terminated	Small molecular drug	[18]
GPI-1337	DMCJLX4	Terminated	NA	[19]
GR-89696	DMTGH8N	Terminated	Small molecular drug	[20]
GT-2342	DMZQHCK	Terminated	Small molecular drug	[21]
L-689560	DMCVY4U	Terminated	Small molecular drug	[22]

This Disease is Treated as An Indication in 6 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
EVP-0334	DMQHFDS	Preclinical	NA	[12]
GSK180	DMNU3SI	Preclinical	Small molecular drug	[13]
IU1	DMJ0A2R	Preclinical	Small molecular drug	[14]
NC043	DMEHO9G	Preclinical	Small molecular drug	[15]
Ro 61-8048	DMWAR1T	Preclinical	Small molecular drug	[13]
UPF-648	DMDVZQ8	Preclinical	Small molecular drug	[13]

This Disease is Treated as An Indication in 30 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AGT-0031	DMVVPHM	Investigative	NA	[23]
BZYX	DMA0GSY	Investigative	NA	[24]
DP-109	DMYUHEN	Investigative	NA	[23]
EHT/AGN-0002	DMHMAA3	Investigative	NA	[23]
EHT/AGN-0003	DMPKD7V	Investigative	NA	[23]
Gene therapy, neurodegenerative diseases	DM79K6C	Investigative	NA	[23]
HSB-13	DMGTFVZ	Investigative	NA	[23]
L-erythro-3-hydroxyaspartate	DMV4OKR	Investigative	Small molecular drug	[25]
Malonic acid	DMM5QXL	Investigative	Small molecular drug	[25]
MDA-106	DMGQVMB	Investigative	NA	[23]
Minokine	DMQ32G5	Investigative	NA	[23]
Nerve growth factor conjugated RAP peptide	DM3AW8X	Investigative	NA	[26]
NeurTriptin	DM6JMLJ	Investigative	NA	[23]
NI-105	DMPK2JO	Investigative	NA	[27]
NLP-61	DMD521Q	Investigative	NA	[23]
NNZ-2591	DM4P1R2	Investigative	NA	[23]
NPRx-30	DMYB2EZ	Investigative	NA	[24]
NS-640	DMHFZDJ	Investigative	NA	[23]
NT-CC-017	DM80MHL	Investigative	NA	[23]
NT-KO-009	DMN2YXJ	Investigative	NA	[23]
NT-KO-012	DM8TBT4	Investigative	NA	[23]
NW-1772	DMRYBK6	Investigative	NA	[28]
PPLs	DMS9V5O	Investigative	NA	[23]
SNX-002	DMJ57DJ	Investigative	NA	[23]
SUVN-1004028	DMQ5GMV	Investigative	NA	[29]
TrkB NAM	DMBZI5F	Investigative	NA	[30]
TTH 02-001	DM5EZ9Q	Investigative	NA	[23]
TTH 03-002	DMK5URL	Investigative	NA	[23]
VAR-10200	DMD7M9L	Investigative	Small molecular drug	[28]
VAR-10300	DMFKTPO	Investigative	Small molecular drug	[31]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7336).
• [3] ClinicalTrials.gov (NCT00000392) Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT01734733) Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01505907) Pharmacokinetic Study of CXB909 in Healthy Male Subjects. U.S. National Institutes of Health.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8430).
• [7] Clinical pipeline report, company report or official report of GlaxoSmithKline
• [8] Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
• [9] Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005568)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001922)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022626)
• [13] Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
• [14] Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
• [15] A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 2014 Apr;24(4):482-96.
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009968)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008742)
• [18] A synthetic superoxide dismutase/catalase mimetic EUK-207 mitigates radiation dermatitis and promotes wound healing in irradiated rat skin. J Invest Dermatol. 2013 Apr;133(4):1088-96.
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010762)
• [20] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1649).
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001928)
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4239).
• [23] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [24] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [25] Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets. 2011 Jun;12(7):1037-55.
• [26] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888).
• [27] Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [29] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9).
• [30] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818).
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3897).